MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Search

Certara Inc

Slēgts

SektorsVeselības aprūpe

9.36 -3.21

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.35

Max

9.46

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

1.5M

Pārdošana

46K

105M

P/E

Sektora vidējais

129.143

87.826

Peļņas marža

1.458

Darbinieki

1,487

EBITDA

-6.5M

23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+25.23% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 25. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-439M

1.4B

Iepriekšējā atvēršanas cena

12.57

Iepriekšējā slēgšanas cena

9.36

Ziņu noskaņojums

By Acuity

50%

50%

187 / 370 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. janv. 22:18 UTC

Tirgus saruna

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

2026. g. 9. janv. 21:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 9. janv. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2026. g. 9. janv. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. janv. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 9. janv. 21:43 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

2026. g. 9. janv. 20:39 UTC

Tirgus saruna

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

2026. g. 9. janv. 20:38 UTC

Tirgus saruna

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

2026. g. 9. janv. 20:36 UTC

Iegādes, apvienošanās, pārņemšana

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

2026. g. 9. janv. 20:30 UTC

Tirgus saruna

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

2026. g. 9. janv. 20:15 UTC

Tirgus saruna

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

2026. g. 9. janv. 20:07 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 9. janv. 20:07 UTC

Tirgus saruna

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

2026. g. 9. janv. 19:58 UTC

Iegādes, apvienošanās, pārņemšana

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

2026. g. 9. janv. 19:42 UTC

Tirgus saruna

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

2026. g. 9. janv. 19:38 UTC

Iegādes, apvienošanās, pārņemšana

Wolters Kluwer Acquires StandardFusion >WTKWY

2026. g. 9. janv. 19:31 UTC

Peļņas

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

2026. g. 9. janv. 19:28 UTC

Peļņas

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

2026. g. 9. janv. 18:30 UTC

Tirgus saruna

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

2026. g. 9. janv. 18:23 UTC

Tirgus saruna

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

2026. g. 9. janv. 17:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2026. g. 9. janv. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. janv. 17:19 UTC

Tirgus saruna

Energy Prices Not Seen Supporting More Drilling -- Market Talk

2026. g. 9. janv. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 9. janv. 17:07 UTC

Tirgus saruna

McDonald's Promotions Appear Successful -- Market Talk

2026. g. 9. janv. 17:06 UTC

Tirgus saruna

Oil Futures on Track for Weekly Gains -- Market Talk

2026. g. 9. janv. 17:05 UTC

Peļņas

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

2026. g. 9. janv. 16:57 UTC

Tirgus saruna

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

2026. g. 9. janv. 16:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 9. janv. 16:46 UTC

Tirgus saruna

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

25.23% augšup

Prognoze 12 mēnešiem

Vidējais 12.11 USD  25.23%

Augstākais 16 USD

Zemākais 9 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

7

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

187 / 370 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat